全文获取类型
收费全文 | 12779篇 |
免费 | 846篇 |
国内免费 | 302篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 334篇 |
妇产科学 | 306篇 |
基础医学 | 1393篇 |
口腔科学 | 291篇 |
临床医学 | 1127篇 |
内科学 | 1144篇 |
皮肤病学 | 304篇 |
神经病学 | 90篇 |
特种医学 | 527篇 |
外国民族医学 | 2篇 |
外科学 | 3339篇 |
综合类 | 2181篇 |
现状与发展 | 2篇 |
预防医学 | 363篇 |
眼科学 | 58篇 |
药学 | 933篇 |
2篇 | |
中国医学 | 506篇 |
肿瘤学 | 920篇 |
出版年
2024年 | 10篇 |
2023年 | 141篇 |
2022年 | 173篇 |
2021年 | 347篇 |
2020年 | 351篇 |
2019年 | 294篇 |
2018年 | 322篇 |
2017年 | 353篇 |
2016年 | 420篇 |
2015年 | 372篇 |
2014年 | 791篇 |
2013年 | 741篇 |
2012年 | 731篇 |
2011年 | 935篇 |
2010年 | 786篇 |
2009年 | 675篇 |
2008年 | 689篇 |
2007年 | 778篇 |
2006年 | 700篇 |
2005年 | 652篇 |
2004年 | 519篇 |
2003年 | 455篇 |
2002年 | 371篇 |
2001年 | 329篇 |
2000年 | 254篇 |
1999年 | 207篇 |
1998年 | 182篇 |
1997年 | 166篇 |
1996年 | 146篇 |
1995年 | 131篇 |
1994年 | 107篇 |
1993年 | 90篇 |
1992年 | 101篇 |
1991年 | 83篇 |
1990年 | 63篇 |
1989年 | 73篇 |
1988年 | 56篇 |
1987年 | 44篇 |
1986年 | 37篇 |
1985年 | 37篇 |
1984年 | 25篇 |
1983年 | 27篇 |
1982年 | 34篇 |
1981年 | 29篇 |
1980年 | 22篇 |
1979年 | 17篇 |
1978年 | 9篇 |
1977年 | 20篇 |
1976年 | 13篇 |
1973年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
3.
目前已用出生免疫错误(IEI)来替代原发性免疫缺陷病这一概念。IEI是一类由单基因突变引起免疫功能异常的遗传性疾病,肝脏和脾脏作为人类重要的免疫器官,与IEI疾病过程中伴发感染、淋巴增殖及自身免疫现象等有重要关联。文章就与IEI相关的肝脾问题进行概述。 相似文献
4.
5.
《International journal of oral and maxillofacial surgery》2022,51(1):98-103
This article outlines a conceptual approach to the reconstruction of jaw deformities associated with abnormalities in the mandibular condyle. The authors describe a hierarchy of reconstruction, emphasizing use of the least invasive and progressing to the most complex and invasive techniques, depending on the nature and severity of the underlying deformity, prior operations, patient age, and stage of growth. Consider joint preservation orthognathic surgical correction, followed by biological techniques for replacement of the condyle, and avoid replacing a functional temporomandibular joint based only on radiographic remodeling and concerns about potential future flare-ups of disease based on anecdotal data. 相似文献
6.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
7.
8.
9.
10.